Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc.

Analysts see strong momentum in some stocks this week, including Kodiak Sciences ($KOD), Archer Aviation ($ACHR), and CleanSpark ($CLSK). While eac...

3 Best Stocks With 75%+ Upside to Buy This Week, According to Analysts

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kodiak Sciences (KOD) and Oruka Therapeutics (ORKA) ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nektar Therapeutics (NKTR), Kodiak Sciences (KOD) an...

Analysts’ Top Healthcare Picks: Nektar Therapeutics (NKTR), Kodiak Sciences (KOD)

The latest update is out from Prologis ( ($PLD) ). On August 5, 2026, Prologis said underwriters J.P. Morgan Securities LLC and BofA Securities, In...

Prologis boosts capital with expanded common stock offering

Prologis ( ($PLD) ) has shared an announcement. On August 5, 2026, Prologis, Inc. disclosed that underwriters J.P. Morgan Securities LLC and BofA S...

Prologis Raises Additional Equity Capital Through Share Offering

Prologis ( ($PLD) ) just unveiled an announcement. On August 4, 2026, Prologis entered into an underwriting agreement with J.P. Morgan Securities L...

Prologis launches major equity offering to fund expansion

An update from Kodal Minerals ( ($GB:KOD) ) is now available. Kodal Minerals said shareholders approved all resolutions at its latest general meeti...

Kodal Minerals Wins Shareholder Backing at General Meeting

Prologis ( ($PLD) ) has provided an update. Prologis has welcomed SEGRO’s board decision that the financial terms of Prologis’ “best and final” pro...

Prologis Gains SEGRO Board Support as Takeover Deadline Extended

In a report released today, Richard Hightower from Barclays assigned a Buy rating to Prologis, with a price target of $156.00. Hightower covers the...

Prologis (PLD) Gets a Buy from Barclays

Berenberg Bank analyst Will Dalby reiterated a Buy rating on Kodal Minerals on July 17 and set a price target of p1.00. The company’s shares closed...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KOD	$40.98	-0.89%	628.19K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KOD	$40.98	-0.9%	628.19K
3
4
5
6

KOD

Get Kodiak Sciences Inc. Data in Excel

Get Kodiak Sciences Inc. Data in Excel